Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF

Annals of Oncology

Volumn 8, Issue 3, 1997, Pages 271-275

  Fox, S B ^a   Engels, K ^a   Comley, M ^a   Whitehouse, R M ^a   Turley, H ^a   Gatter, K C ^a   Harris, A L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

breast cancer; chemotherapy; platelet derived endothelial cell growth factor; prediction; thymidine phosphorylase

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; THYMIDINE PHOSPHORYLASE;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

EID: 0030895912     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008280110558     Document Type: Article

References (22)

1. Gasparini G, Pozza F, Harris AL. Evaluating the potential usefulness of new prognostic and predictive indicators in nodenegative breast cancer patients, J Natl Cancer Inst 1993; 85: 1206-19.
2. Moghaddam A, Zhang HT, Fan TP et al. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 1995; 92: 998-1002.
3. Asai K, Nakanishi K, Isobe I et al. Neurotrophic action of gliostatin on cortical neurons. Identity of gliostatin and plateletderived endothelial cell growth factor. J Biol Chem 1992; 267: 20311-6.
4. Heldin NE, Usuki K, Bergh J et al. Differential expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human lung carcinoma cell lines. Br J Cancer 1993; 68: 708-11.
5. Kono A, Hara Y, Sugata S et al. Substrate specificity of a thymidine phosphorylase in human liver tumor. Chem Pharm Bull 1984; 32: 1919-21.
6. Yoshimura A, Kuwazuru Y, Furukawa T et al. Purification and tissue distribution of human thymidine phosphorylase: high expression in lymphocytes, reticulocytes and tumors. Biochim Biophys Acta 1990; 1034: 107-13.
7. Reynolds K, Farzaneh F, Collins WP et al. Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor. J Natl Cancer Inst 1994; 86: 1234-8.
8. Takebayashi Y, Yamada K, Maruyama I et al. The expression of thymidine phosphorylase and thrombomodulin in human colorectal carcinomas. Cancer Lett 1995; 92: 1-7.
9. Maeda K, Chung YS, Ogawa Y et al. Malignancy of gastric cancer analysed by expression of thymidine phosphorylase. Gan To Kagaku Ryoho 1995; 22: 679-82.
10. Pauly JL, Schuller MG, Zelcer AA et al. Identification and comparative analysis of thymidine phosphorylase in the plasma of healthy subjects and cancer patients. J Natl Cancer Inst 1977; 58: 1587-90.
11. Fox SB, Westwood M, Moghaddam A et al. The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cance epithelium and endothelium. Br J Cancer 1996; 73: 275-80.
12. Piper AA, Tattersall MHN, Fox RM. The activities of thymidine metabolising enzymes during the cell cycle of a human lymphocyte cell line LAZ-007 synchronised by centrifugal elutriation. Biochim Biophys Acta 1980; 633: 400-9.
13. Schwartz EL, Baptiste N, Wadler S et al. Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil. J Biol Chem 1995; 270: 19073-7.
14. Needham GK, Nicholson S, Angus B et al. Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors. Cancer Res 1988; 48: 6603-7.
15. Horak ER, Leek R, Klenk N et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992; 340: 1120-4.
16. Haraguchi M, Furukawa T, Sumizawa T et al. Sensitivity of human KB cells expressing platelet-derived endothelial cell growth factor to pyrimdine antimetabolites. Cancer Res 1993; 53: 5680-2.
17. Johnston PG, Lenz HJ, Leichman CG et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55: 1407-12.
18. Lowe S, Ruley H, Jacks T et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 266: 807-10.
19. Schwartz EL, Baptiste N, O'Connor CJ et al. Potentiation of the antitumour activity of 5-fluorouracil in colon carcinoma cells by the combination of interferon and deoxyribonucleosides results from complementary effects on thymidine phosphorylase. Cancer Res 1994; 54: 1472-8.
20. Ho CK, Ou BR, Hsu ML et al. Induction of thymidine kinase activity and clonal growth of certain leukemic cell lines by a granulocyte-derived factor. Blood 1990; 75: 2438-44.
21. Eda H, Fujimoto K, Watanabe S et al. Cytokines induce thymidine phosphorylase expression in tumor cell and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 1993; 32: 333-8.
22. Schwartz EL, Baptiste N, Megati S et al. 5-Ethoxy-2′-deoxyuridine. a novel substrate for thymidine phosphorylase, potentiates the antitumor activity of 5-fluorouracil when used in combination with interferon, an inducer of thymidine phosphorylase expression. Cancer Res 1995; 55: 3543-50.